MCID: PRP021
MIFTS: 40

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 11 14
Peripheral Nervous System Neoplasms 43 71
Nerve Sheath Neoplasm 11 75
Neoplasm of Peripheral Nerve 11
Nerve Sheath Neoplasms 43
Nerve Sheath Tumors 71
Tumor of Pns 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1192
NCIt 49 C3321 C4972
SNOMED-CT 68 126980002 189946005
UMLS 71 C0031118 C0206727

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology: 11 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary: Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to autonomic nervous system neoplasm and melanoma, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are Cell differentiation - expanded index and Interactions between immune cells and microRNAs in tumor microenvironment. The drugs Cyclophosphamide and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, tongue and breast.

Wikipedia: 75 A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up... more...

Related Diseases for Peripheral Nervous System Neoplasm

Diseases in the Peripheral Nervous System Neoplasm family:

Peripheral Nervous System Benign Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 32.3 MYCN MIR9-1 MIR542 MIR380 MIR34A MIR338
2 melanoma 30.7 NF1 MIR34A MIR338 MIR27A MIR21 MIR193A
3 malignant cardiac peripheral nerve sheath neoplasm 11.3
4 malignant triton tumor 11.3
5 glioma 10.6 NF1 MIR34A MIR21 MIR17
6 mature t-cell and nk-cell lymphoma 10.5 MIR21 MIR199A1 MIR17 KDM4C H2AC18
7 interstitial lung disease 10.5 MIR29A MIR21 MIR199A1 H2AC18
8 ovarian clear cell carcinoma 10.5 MIR9-1 MIR21 MIR199A1 H2AC18
9 skeletal muscle cancer 10.5 NF1 MYCN MIR9-1 MIR199A1 H2AC18
10 chromosomal deletion syndrome 10.5 MIR9-1 MIR21 MIR17 KDM4C H2AC18
11 muscle cancer 10.5 NF1 MYCN MIR9-1 MIR199A1 H2AC18
12 primary cutaneous t-cell non-hodgkin lymphoma 10.5 MIR34A MIR21 MIR17 KDM4C H2AC18
13 cystadenocarcinoma 10.5 NF1 MIR21 MIR199A1
14 cystic echinococcosis 10.5 MIR542 MIR21 H2AC18
15 chromosomal disease 10.5 MIR9-1 MIR21 MIR199A1 MIR17 KDM4C H2AC18
16 lung disease 10.5 MIR21 MIR199A1 MIR17 MIR145 H2AC18
17 heart valve disease 10.5 MIR34A MIR21 MIR199A1 MIR17 MIR124-1 H2AC18
18 physical disorder 10.5 MIR9-1 MIR21 MIR199A1 MIR17 KDM4C H2AC18
19 infratentorial cancer 10.5 NF1 MYCN MIR9-1 MIR199A1 MIR17 KDM4C
20 melanoma in congenital melanocytic nevus 10.5 MIR21 MIR199A1 KDM4C H2AC18
21 extrinsic cardiomyopathy 10.5 MIR21 MIR199A1 MIR17 H2AC18
22 uveal disease 10.5 MIR9-1 MIR199A1 MIR17 H2AC18
23 aortic valve disease 2 10.5 MIR34A MIR21 MIR199A1 MIR17 MIR124-1 H2AC18
24 mature b-cell neoplasm 10.5 MIR9-1 MIR199A1 MIR181A1 MIR17 KDM4C H2AC18
25 brain stem cancer 10.5 NF1 KDM4C H2AC18
26 learning disability 10.5 NF1 MYCN MIR9-1 H2AC18
27 intrahepatic cholangiocarcinoma 10.5 MIR199A1 MIR17 KDM4C H2AC18
28 pleural cancer 10.5 MIR21 MIR199A1 MIR193A MIR17 H2AC18
29 peripheral t-cell lymphoma 10.5 MIR21 MIR199A1 MIR17 KDM4C H2AC18
30 muscle tissue disease 10.5 MIR9-1 MIR21 MIR199A1 KDM4C H2AC18
31 serous cystadenocarcinoma 10.5 NF1 MIR21 MIR199A1 H2AC18
32 lipid storage disease 10.5 MIR9-1 MIR34A MIR29A MIR21 MIR199A1 MIR17
33 thyroid gland disease 10.5 MIR9-1 MIR199A1 MIR181A1 MIR17 H2AC18
34 cardiovascular organ benign neoplasm 10.5 NF1 MIR199A1 MIR17 H2AC18
35 spinal cord disease 10.5 NF1 MIR9-1 MIR29A MIR199A1 KDM4C H2AC18
36 pleural disease 10.5 MIR21 MIR199A1 MIR193A MIR17 H2AC18
37 specific developmental disorder 10.5 NF1 MIR9-1 MIR21 KDM4C H2AC18
38 autoimmune disease of musculoskeletal system 10.5 MIR34A MIR27A MIR21 MIR199A1 MIR17 H2AC18
39 heart conduction disease 10.5 MIR21 MIR199A1 MIR17 MIR145 MIR124-1 H2AC18
40 intrinsic cardiomyopathy 10.5 MIR27A MIR21 MIR199A1 MIR17 MIR124-1 H2AC18
41 ovarian serous carcinoma 10.5 MIR29A MIR27A MIR21 MIR199A1 MIR145 H2AC18
42 intestinal benign neoplasm 10.5 MIR21 MIR199A1 MIR193A MIR17 H2AC18
43 leiomyoma, uterine 10.5 MIR542 MIR34A MIR335 MIR27A MIR21
44 lysosomal storage disease 10.5 MIR9-1 MIR34A MIR29A MIR21 MIR199A1 MIR17
45 central nervous system benign neoplasm 10.5 NF1 MYCN MIR9-1 MIR34A MIR21 MIR199A1
46 eye degenerative disease 10.5 MIR9-1 MIR335 MIR27A MIR17 H2AC18
47 atypical teratoid rhabdoid tumor 10.5 NF1 MYCN MIR124-1 H2AC18
48 retinal vascular disease 10.5 MIR335 MIR27A MIR21 MIR199A1 MIR17 H2AC18
49 gastrointestinal system benign neoplasm 10.5 MIR21 MIR199A1 MIR193A MIR17 H2AC18
50 diffuse astrocytoma 10.5 NF1 KDM4C H2AC18

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
4
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
5
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
6
Palifosfamide Investigational Phase 2, Phase 3 31645-39-3 100427
7 Anti-Bacterial Agents Phase 2, Phase 3
8 Alkylating Agents Phase 2, Phase 3
9 Antineoplastic Agents, Alkylating Phase 2, Phase 3
10 Antibiotics, Antitubercular Phase 2, Phase 3
11 Liposomal doxorubicin Phase 2, Phase 3
12
Imatinib Mesylate Phase 2, Phase 3 220127-57-1
13 Protein Kinase Inhibitors Phase 2, Phase 3
14
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
15
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
17
Dacarbazine Approved, Investigational Phase 2 4342-03-4 2942 5351166
18
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
19
Adenosine Approved, Investigational Phase 2 58-61-7 60961
20
Trastuzumab Approved, Investigational Phase 2 180288-69-1
21
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
23
Lenograstim Approved, Investigational Phase 2 135968-09-1
24
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
25
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 6473866 445643
26
Nivolumab Approved Phase 2 946414-94-4
27
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
28
Pancrelipase Approved, Investigational Phase 1, Phase 2 53608-75-6 8519
29
Etoposide Approved Phase 2 33419-42-0 36462
30
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
31
Ipilimumab Approved Phase 2 477202-00-9
32
Melphalan Approved Phase 2 148-82-3 4053 460612
33
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
34
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
35
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
36
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
37
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
40
Durvalumab Approved, Investigational Phase 2 1428935-60-7
41
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
42
Gemcitabine Approved Phase 1, Phase 2 95058-81-4, 122111-03-9 60750
43
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
44
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 1, Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
45
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
46
D-Threonine Approved, Experimental, Nutraceutical Phase 2 72-19-5, 632-20-2 205 6288
47
Lorvotuzumab mertansine Investigational Phase 2 1008106-64-6
48
Ado-Trastuzumab Emtansine Phase 2
49
Maytansine Phase 2
50 Angiogenesis Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
2 An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
3 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
4 A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
5 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
6 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
7 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
8 A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Completed NCT02452554 Phase 2
9 Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors Completed NCT01661283 Phase 2 everolimus;bevacizumab
10 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
11 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
12 U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II Completed NCT00068367 Phase 2 erlotinib hydrochloride
13 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
14 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
15 Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
16 A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion Recruiting NCT05245500 Phase 1, Phase 2 MRTX1719
17 A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST) Recruiting NCT04872543 Phase 2 ASTX727
18 A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors Recruiting NCT03611868 Phase 1, Phase 2 APG-115+Pembrolizumab
19 Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Recruiting NCT04917042 Phase 2 Tazemetostat
20 A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors Recruiting NCT04530487 Phase 2 Cyclosporine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus;Thiotepa
21 Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors) Recruiting NCT05011019 Phase 1, Phase 2 AL2846 capsules
22 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
23 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
24 A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors Active, not recruiting NCT03872427 Phase 2 Telaglenastat Hydrochloride
25 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
26 SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
27 A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors Not yet recruiting NCT05642455 Phase 1, Phase 2
28 A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112) Not yet recruiting NCT05253131 Phase 2 Selumetinib
29 A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Terminated NCT02691026 Phase 2 Pembrolizumab
30 A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma Terminated NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
31 A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
32 A Phase 2 Study of CPI-0610, a Small Molecule Inhibitor of Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
33 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
34 A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors Completed NCT00931931 Phase 1
35 Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis Completed NCT02211768 Phase 1 [18F]-FLT-PET/CT scans
36 First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Recruiting NCT04222413 Phase 1 Metarrestin
37 Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT04483778 Phase 1
38 Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor Recruiting NCT02700230 Phase 1
39 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Recruiting NCT04897321 Phase 1 Fludarabine;Cyclophosphamide;MESNA;B7-H3 CAR T cells
40 A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas Recruiting NCT04811196 Phase 1 Selinexor
41 Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
42 Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Recruiting NCT04465643 Phase 1 Nivolumab;Ipilimumab
43 A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas Active, not recruiting NCT03009201 Phase 1 Doxorubicin Hydrochloride;Ribociclib
44 A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma Active, not recruiting NCT04420975 Phase 1
45 A Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors) Not yet recruiting NCT05107037 Phase 1 TQ-B3234 capsule
46 A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma Withdrawn NCT03880123 Phase 1 Selinexor;Ixazomib
47 Analysis of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients Unknown status NCT01218139
48 Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis Unknown status NCT01777451
49 HiPPI: A Phase 2 Trial of Hypofractionated Pencil Beam Scanning Proton Therapy for Benign Intracranial Tumors Recruiting NCT04278118
50 Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology Recruiting NCT04648462

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

Organs/tissues related to Peripheral Nervous System Neoplasm:

MalaCards : T Cells, Tongue, Breast, Skin

Publications for Peripheral Nervous System Neoplasm

Articles related to Peripheral Nervous System Neoplasm:

(show all 39)
# Title Authors PMID Year
1
Retroperitoneal Recurrence of Melanotic Schwannoma on 18F-FDG PET/CT. 62
34560691 2021
2
Breast Shwannoma - Time to explore alternative management strategy? 62
34273600 2021
3
18F-FDG PET/CT imaging for aggressive melanotic schwannoma of the L3 spinal root: A case report. 62
33663098 2021
4
Intraneural perineurioma: a retrospective study of 19 patients. 62
30637060 2018
5
Pilomatrixoma of the Neck/Shoulder Region Mimicking a Rapidly Growing Neoplasm of Peripheral Nerve Sheath Origin in Neurofibromatosis Type 1. 62
29187472 2017
6
A Rare Case of Aggressive Melanotic Schwannoma Occurred in Spinal Nerve of a 59-Year-Old Male. 62
28372342 2017
7
Primary bilateral corneal nerve sheath neoplasm in a dog. 62
27352771 2017
8
Schwannoma of the tongue. 62
28049116 2016
9
Melanotic schwannoma of the L5 root. 62
26969197 2016
10
Denervation of the Tensor Veli Palatini Muscle and Effusion in the Tympanic Cavity. 62
26535464 2015
11
Primary intraosseous schwannoma in tibial epiphysis with unique immunohistochemical phenotype: a case report. 62
24326824 2014
12
Reverse adipofascial flap after resection of a malignant perineurioma of the forearm. 62
24992065 2014
13
Intraosseous neurilemmoma of the proximal ulna. 62
25460435 2014
14
Peripheral tumor and tumor-like neurogenic lesions. 62
21561733 2013
15
Melanotic schwannoma of the cervical spine progressing with pulmonary metastasis: case report. 62
24077273 2013
16
Schwannoma in anterior mediastinum with massive pericardial effusion. 62
23239781 2012
17
Intravascular schwannoma. 62
22042258 2011
18
A primitive neuroectodermal tumor with extension into the cranial vault in a dog. 62
22547846 2011
19
Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies. 62
21383118 2011
20
Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. 62
19540561 2009
21
Multiple cutaneous sclerosing perineuriomas: an extensive presentation with involvement of the bilateral upper extremities. 62
19187114 2009
22
Rare nerve lesions of non-nerve sheath origin: a 17-year retrospective series. 62
19722745 2009
23
Successful resection of a primary left ventricular schwannoma. 62
17462424 2007
24
Perineurioma: a distinctive and underrecognized peripheral nerve sheath neoplasm. 62
17425397 2007
25
Incidentally discovered adrenal schwannoma. 62
17651570 2007
26
Recurrent plexiform schwannoma in vestibular mucosa. 62
16681871 2006
27
Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation. 62
16538053 2006
28
[A rare case of schwannoma in the parotid gland]. 62
16117408 2005
29
Composite dermatofibrosarcoma protuberans-giant cell fibroblastoma recurring as Bednár tumor-giant cell fibroblastoma with mucoid lakes and with amputation neuroma. 62
12629865 2002
30
Psammomatous malignant melanoma arising in an intradermal naevus. 62
11737307 2001
31
Nerve sheath myxoma (neurothekeoma) in the tongue of a newborn. 62
10884639 2000
32
[Malignant schwannoma of parotid gland. Case report and review of literature]. 62
11070704 2000
33
Intraventricular perineurioma: case report. 62
9848865 1998
34
Perineurioma of the finger: case report of a rare peripheral nerve sheath neoplasm of pure perineurial cell lineage. 62
9556280 1998
35
Perineurioma. 62
7660217 1995
36
Meningioma-like tumor of the skin. An ultrastructural and immunohistochemical study. 62
7687827 1993
37
Human peripheral nerve sheath neoplasm: expression of Schwann cell-related markers and their relation to malignant transformation. 62
1656253 1991
38
Magnetic resonance appearance of peripheral nerve sheath tumors. 62
1900374 1991
39
Benign nerve sheath neoplasm: a light microscopic and ultrastructural evaluation with differential diagnostic guidelines. 62
6948097 1981

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

GO Terms for Peripheral Nervous System Neoplasm

Cellular components related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.74 MIR9-1 MIR542 MIR338 MIR335 MIR29A MIR27A
2 extracellular vesicle GO:1903561 9.43 MIR34A MIR29A MIR27A MIR21 MIR193A MIR17

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.13 MYCN MIR34A MIR29A MIR27A MIR21 MIR17
2 negative regulation of angiogenesis GO:0016525 9.87 MIR145 MIR193A MIR21 MIR29A MIR34A NF1
3 negative regulation of gene expression GO:0010629 9.85 MYCN MIR9-1 MIR34A MIR338 MIR29A MIR27A
4 positive regulation of endothelial cell migration GO:0010595 9.78 MIR29A MIR21 MIR199A1
5 negative regulation of protein kinase B signaling GO:0051898 9.77 MIR34A MIR29A MIR145
6 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.77 NF1 MIR27A MIR21 MIR17
7 miRNA-mediated gene silencing GO:0035195 9.77 MIR9-1 MIR542 MIR34A MIR338 MIR335 MIR29A
8 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.76 NF1 MIR34A MIR21
9 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.73 MIR9-1 MIR29A MIR27A MIR21 MIR17 MIR145
10 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.71 MIR9-1 MIR21 MIR149
11 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.7 MIR149 MIR193A MIR199A1
12 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.69 MIR21 MIR199A1 MIR145
13 positive regulation of vascular endothelial cell proliferation GO:1905564 9.67 MIR29A MIR27A MIR21
14 negative regulation of cell migration GO:0030336 9.65 MIR145 MIR149 MIR21 MIR29A MIR335 MIR338
15 negative regulation of vascular endothelial growth factor production GO:1904046 9.61 MIR34A MIR199A1 MIR17
16 positive regulation of connective tissue replacement GO:1905205 9.59 MIR34A MIR199A1
17 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 MIR27A MIR21
18 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR27A MIR199A1 MIR17
19 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR199A1 MIR17
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.56 MIR21 MIR17
21 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR21 MIR17
22 positive regulation of cellular response to hypoxia GO:1900039 9.48 MIR21 MIR145

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 MIR9-1 MIR34A MIR338 MIR335 MIR29A MIR27A
2 mRNA base-pairing translational repressor activity GO:1903231 9.4 MIR9-1 MIR34A MIR338 MIR335 MIR29A MIR27A

Sources for Peripheral Nervous System Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....